Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) (PiSCATIN)

  • End date
    May 15, 2027
  • participants needed
  • sponsor
    Annika Bergquist
Updated on 6 May 2022


This is a randomized, double-blind, placebo controlled multicenter study.

A total of 700 patients will be included.

The study will include patients with primary sclerosing cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver transplantation, cholangiocarcinoma or bleeding from esophageal varices.

Subjects will be randomized (1:1) between Simvastatin and placebo.

Condition Primary Sclerosing Cholangitis
Treatment simvastatin 40mg, Placebo Oral Tablet
Clinical Study IdentifierNCT04133792
SponsorAnnika Bergquist
Last Modified on6 May 2022


Yes No Not Sure

Inclusion Criteria

PSC verified by cholangiography or liver biopsy, with or without irritable bowel disease (IBD)
Men and women between ≥18 years and ≤75 years
Written informed consent
A magnetic resonance imaging (MRI) or Magnetic resonance cholangiopancreatography (MRCP) performed within 4 months prior to randomization
Colonoscopy performed within 24 months prior to randomization, if known IBD
For women of childbearing potential efficient contraceptive

Exclusion Criteria

Subjects on waiting list for transplantation
Transplanted subjects
Previous variceal bleeding
Previous hepatobiliary malignancy
Subjects with secondary sclerosing cholangitis
Intake of any type of statins within 3 months prior to randmization
Known intolerance to simvastatin
Pregnancy or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note